Literature DB >> 8899002

TNF-mediated cytotoxicity and resistance in human prostate cancer cell lines.

Y Nakajima1, A M DelliPizzi, C Mallouh, N R Ferreri.   

Abstract

BACKGROUND: The contribution of TNF receptor (TNF-R) expression was investigated with respect to TNF sensitivity or insensitivity for androgen-dependent and androgen-independent human prostate cancer (PCA) cell lines, respectively.
METHODS: Flow cytometric analyses using monoclonal antibodies against the 55-kDa receptor (TNF-R1) and the 75-kDa receptor (TNF-R2) indicated that both receptors were expressed on all three cell lines.
RESULTS: Moreover, expression of TNF-R1 was greater than expression of TNF-R2 in these PCA cells. All three PCA cell lines produced IL-6. However, IL-6 production was enhanced when TNF-insensitive JCA-1 and PC-3 cells, but not TNF-sensitive LNCaP cells, were treated with rTNF (10(-9) M).
CONCLUSIONS: These data suggest that the lack of an antiproliferative effect of rTNF on the androgen-independent PCA cell lines PC-3 and JCA-1 is not due to the failure of these cells to express TNF-R, but may be related to the differences in TNF-mediated IL-6 expression by these PCA cell lines.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8899002     DOI: 10.1002/(SICI)1097-0045(199611)29:5<296::AID-PROS4>3.0.CO;2-8

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  9 in total

1.  Connexin43 increases the sensitivity of prostate cancer cells to TNFalpha-induced apoptosis.

Authors:  Min Wang; Viviana M Berthoud; Eric C Beyer
Journal:  J Cell Sci       Date:  2007-01-02       Impact factor: 5.285

2.  Dihydrotestosterone Increases Cytotoxic Activity of Macrophages on Prostate Cancer Cells via TRAIL.

Authors:  Geun Taek Lee; Jeong Hyun Kim; Seok Joo Kwon; Mark N Stein; Jeong Hee Hong; Naoya Nagaya; Sachin Billakanti; Melina Minji Kim; Wun-Jae Kim; Isaac Yi Kim
Journal:  Endocrinology       Date:  2019-09-01       Impact factor: 4.736

3.  Reduced tumor necrosis factor receptor-associated death domain expression is associated with prostate cancer progression.

Authors:  Diping Wang; R Bruce Montgomery; Lucy J Schmidt; Elahe A Mostaghel; Haojie Huang; Peter S Nelson; Donald J Tindall
Journal:  Cancer Res       Date:  2009-12-15       Impact factor: 12.701

4.  Androgens regulate TRAIL-induced cell death in prostate cancer cells via multiple mechanisms.

Authors:  Diping Wang; Ji Lu; Donald J Tindall
Journal:  Cancer Lett       Date:  2013-02-09       Impact factor: 8.679

Review 5.  Autophagy in prostate cancer and androgen suppression therapy.

Authors:  Elio Ziparo; Simonetta Petrungaro; Elettra Sara Marini; Donatella Starace; Silvia Conti; Antonio Facchiano; Antonio Filippini; Claudia Giampietri
Journal:  Int J Mol Sci       Date:  2013-06-06       Impact factor: 5.923

Review 6.  Targeting the androgen receptor in triple-negative breast cancer: current perspectives.

Authors:  Alain Mina; Rachel Yoder; Priyanka Sharma
Journal:  Onco Targets Ther       Date:  2017-09-20       Impact factor: 4.147

7.  Enhancement of antiproliferative effects of interleukin-1beta and tumor necrosis factor-alpha on human prostate cancer LNCaP cells by coculture with normal fibroblasts through secreted interleukin-6.

Authors:  M Kawada; M Ishizuka; T Takeuchi
Journal:  Jpn J Cancer Res       Date:  1999-05

8.  SFMBT2 (Scm-like with four mbt domains 2) negatively regulates cell migration and invasion in prostate cancer cells.

Authors:  Jungsug Gwak; Jee Yoon Shin; Kwanghyun Lee; Soon Ki Hong; Sangtaek Oh; Sung-Ho Goh; Won Sun Kim; Bong Gun Ju
Journal:  Oncotarget       Date:  2016-07-26

9.  PTEN deficiency promotes macrophage infiltration and hypersensitivity of prostate cancer to IAP antagonist/radiation combination therapy.

Authors:  Chris W D Armstrong; Pamela J Maxwell; Chee Wee Ong; Kelly M Redmond; Christopher McCann; Jessica Neisen; George A Ward; Gianni Chessari; Christopher Johnson; Nyree T Crawford; Melissa J LaBonte; Kevin M Prise; Tracy Robson; Manuel Salto-Tellez; Daniel B Longley; David J J Waugh
Journal:  Oncotarget       Date:  2016-02-16
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.